Tofacitinib (Selective Janus Kinase Inhibitor 1 and 3): A promising therapy for the treatment of alopecia areata: A case report of six patients
January 2018
in “International Journal of Trichology”
TLDR Tofacitinib helped regrow hair in patients with alopecia, with few side effects.
In 2018, a case report studied the effects of Tofacitinib, a selective Janus Kinase inhibitor 1 and 3, on six patients with alopecia areata and alopecia universalis. All patients showed significant hair regrowth after treatment, with effects noticeable by the end of 12 weeks. Four patients continued treatment and were under follow-up, with one not relapsing after stopping the drug for 4 months, and another developing alopecia areata patches in the eyebrows within 2 months of stopping Tofacitinib. Two patients experienced acneiform eruptions, managed with topicals. The report concluded that Tofacitinib effectively treated alopecia without significant adverse side effects, but recommended further controlled studies to confirm its safety and efficacy.
View this study on journals.lww.com →
Cited in this study
research Tofacitinib for the treatment of alopecia areata and variants in adolescents
Tofacitinib helped regrow hair in most adolescents with alopecia areata, but more research is needed.
research Tofacitinib for the treatment of severe alopecia areata and variants: A study of 90 patients
Tofacitinib is effective and safe for severe hair loss, but full regrowth is less likely after 10 years of hair loss.
research Safety and efficacy of the JAK inhibitor tofacitinib citrate in patients with alopecia areata
Tofacitinib is safe and effective for severe alopecia areata, but hair loss may return 2 months after stopping treatment.
research Oral ruxolitinib induces hair regrowth in patients with moderate-to-severe alopecia areata
Ruxolitinib effectively regrows hair in most patients with severe hair loss.
research Efficacy of tofacitinib in treatment of alopecia universalis in two patients
Tofacitinib was effective in treating hair loss in two patients with alopecia universalis.
research Topical Ruxolitinib for the Treatment of Alopecia Universalis
research Pharmacologic inhibition of JAK-STAT signaling promotes hair growth
Blocking JAK-STAT signaling can lead to hair growth.
research Reversal of Alopecia Areata Following Treatment With the JAK1/2 Inhibitor Baricitinib
A patient with Alopecia Areata had complete hair regrowth after using the drug baricitinib.
research Killing Two Birds with One Stone: Oral Tofacitinib Reverses Alopecia Universalis in a Patient with Plaque Psoriasis
A man with severe hair loss and skin disease regrew his hair with no side effects after taking tofacitinib.
research Alopecia areata is driven by cytotoxic T lymphocytes and is reversed by JAK inhibition
Alopecia areata can be reversed by JAK inhibitors, promoting hair regrowth.
research Alopecia Areata
Alopecia Areata is an autoimmune condition causing hair loss with no cure and treatments that often don't work well.
research Interventions for alopecia areata
Current treatments for alopecia show no significant long-term benefits.
research Familial aggregation of alopecia areata
Alopecia areata, a common autoimmune hair loss condition, often runs in families.
Related
research Successful Treatment of Severe Alopecia Areata With Oral or Topical Tofacitinib.
Oral and topical tofacitinib can help regrow hair in people with severe alopecia areata.